Methoxy-substituted hydroxychalcone reduces biofilm production, adhesion, and surface motility of Acinetobacter baumannii by inhibiting ompA gene expression by Ušjak, Dušan et al.
1Department of Microbiology and Immunology, University of Belgrade - Faculty of Pharmacy, Serbia 
2Laboratory for Molecular Microbiology, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia 
3Department of Pharmaceutical Chemistry, University of Belgrade - Faculty of Pharmacy, Serbia 
4Institute of Technical Sciences of the Serbian Academy of Sciences and Arts, Serbia 
1. Colquhoun JM, Rather PN. Insights Into Mechanisms of Biofilm Formation in Acinetobacter baumannii and Implications for Uropathogenesis. Front Cell Infect Microbiol. 2020, 10, 253. 
2. Nie D, Hu Y, Chen Z, Li M, Hou Z, Luo X, Mao X, Xue X. Outer membrane protein A (OmpA) as a potential therapeutic target for Acinetobacter baumannii infection. J Biomed Sci. 2020, 27, 26. 
3. López-Rojas R, Smani Y, Pachón J. Treating multidrug-resistant Acinetobacter baumannii infection by blocking its virulence factors. Expert Rev Anti Infect Ther. 2013, 11, 231-233. 
4. Rani A, Anand A, Kumar K, Kumar V. Recent developments in biological aspects of chalcones: the odyssey continues. Expert Opin Drug Discov. 2019, 14, 249-288. 
AIMS 
• Carbapenem-resistant Acinetobacter baumannii is recognized as a top priority pathogen for development of new therapeutic strategies by WHO and CDC.1  
• Outer membrane protein A (OmpA) is a major virulence factor in A. baumannii, involved in adhesion and invastion of host cells, cytotoxicity, motility, biofilm production,  
OMVs biogenesis, immune evasion, and AMR.2  
• Targeting virulence is a novel therapeutic strategy that provides possibility to disarm pathogens, while minimally affecting their growth, thereby slowing down the selection 
of resistant mutants.3  
• Chalcones are compounds that shown plenty of potent antimicrobial and antivirulence activities in multiple studies.4 
1) Select chalcone with the most potent 
antibiofilm activity against A. baumannii. 
2) Determine its crystallinity and thermal 
properties. 
3) Investigate its activity against biofilm-
related virulence factors gene 
expression in A. baumannii. 
4) Confirm its antivirulence activity through 
the evaluation of  phenotypic features 
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Only compound 1 displayed 
significant antibiofilm activity 
against both strains 
Hydroxychalcones were obtained by base-
catalyzed Claisen-Schmidt condensation and 
the structures were verified by FTIR, 1H NMR, 
13C NMR and ESI-MS. 
Conclusions: 
 Methoxy-substituted hydroxychalcone (compound 1)  exhibits the most 
potent antibiofilm activity against A. baumannii. 
 Gene expression of  virulence factors OmpA, Bap, and AbaI is 
significantly inhibited by methoxy-substituted hydroxychalcone. 
 The expression  of  ompA, whose protein product is associated with 
numerous virulence traits, is downregulated by 1.58-fold to 1.85-fold at 70 
μg ml-1 → this is confirmed through the inhibition of  ECM-mediated 
adhesion and surface motility. 
 Methoxy-substituted hydroxychalcone can be considered as an 
appropriate antivirulence drug candidate  against A. baumannii. 
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Optical microscopy revealed highly 
crystalline nature of compound 1. TGA/DTA 
revealed that it is stable up to 250°C, whereas 
DSC detected melting temperature at 101.4°C. 
Tested sub-MICs do 
not inhibit cell growth, 
so compound 1 could 
be considered as a 
suitable antivirulence 
drug candidate 




The mRNA expression of all 
examined virulence factor genes is 
significantly downregulated by 
compound 1 at all tested 
concentrations. Dose-dependent 
inhibition of ompA expression was 
achieved in both strains. The 
expression of abaI was not 
detected in 766. 
Fibronectin- and collagen-mediated adhesion 
is significantly inhibited by compound 1. ATCC 
19606 cells were almost completely deprived of 
its binding ability at 70 μg ml-1. Production of 
AHLs is dose-dependetly reduced in ATCC 
19606. Surface motility is substantially 
inhibited in 766 at 70 and 35 μg ml-1. The 
motility was not exhibited by ATCC 19606. 
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